In the latest trading session, 0.7 million TransCode Therapeutics Inc (NASDAQ:RNAZ) shares changed hands as the company’s beta touched 0.64. With the company’s most recent per share price at $0.68 changing hands around $0.07 or 11.88% at last look, the market valuation stands at $11.79M. RNAZ’s current price is a discount, trading about -2942.65% off its 52-week high of $20.69. The share price had its 52-week low at $0.22, which suggests the last value was 67.65% up since then. When we look at TransCode Therapeutics Inc’s average trading volume, we note the 10-day average is 1.34 million shares, with the 3-month average coming to 2.18 million.
TransCode Therapeutics Inc (NASDAQ:RNAZ) trade information
Instantly RNAZ is in green as seen in intraday trades today. With action 0.49%, the performance over the past five days has been green. The company’s shares are showing year-to-date downside of -89.65%, with the 5-day performance at 0.49% in the green. However, in the 30-day time frame, TransCode Therapeutics Inc (NASDAQ:RNAZ) is 63.70% up. Looking at the short shares, we see there were 1.38 million shares sold at short interest cover period of 0.45 days.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
TransCode Therapeutics Inc (RNAZ) estimates and forecasts
Data shows that the TransCode Therapeutics Inc share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot 55.14% over the past 6 months, a 98.01% in annual growth rate that is considerably higher than the industry average of 17.50%.
Consensus estimates given by 1 financial analysts project the company’s revenue in the current quarter to hit an average of 300k. 1 analysts are of the opinion that TransCode Therapeutics Inc’s revenue for the current quarter will be 300k.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -28.81%. The 2024 estimates are for TransCode Therapeutics Inc earnings to increase by 98.01%.
RNAZ Dividends
TransCode Therapeutics Inc is expected to release its next quarterly earnings report on 2024-Aug-14.
TransCode Therapeutics Inc (NASDAQ:RNAZ)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 0.03% of TransCode Therapeutics Inc shares while 11.46% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 11.47%.
Among Mutual Funds, the top two as of Aug 31, 2024 were Fidelity Extended Market Index Fund and Fidelity NASDAQ Composite Index Fund. With 36.71 shares estimated at $25476.0 under it, the former controlled 0.21% of total outstanding shares. On the other hand, Fidelity NASDAQ Composite Index Fund held about 0.01% of the shares, roughly 1.09 shares worth around $759.0.
